Physician
Pello, Natasha
Pello, Natasha was paid $1.25M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 15% of everything it billed.
33Billing provider infoPELLO, NATASHA
ELGIN, IL 60123
ELGIN, IL 60123
33aNPI1609909217assigned 03/13/2007
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.25M
24GClaims156,489
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#55 of 398
Median peer was paid$66K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 240 | $5K | |
| 2019 | 574 | $12K | |
| 2020 | 562 | $16K | |
| 2021 | 54,804 | $491K | |
| 2022 | 41,652 | $341K | |
| 2023 | 32,258 | $223K | |
| 2024incomplete | 26,399 | $159K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 15% | 4,314 | 3,663 | $185K |
| 80053 | Comprehensive metabolic panel | 9.2% | 22,192 | 14,231 | $115K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.7% | 4,489 | 3,813 | $108K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.3% | 27,300 | 16,540 | $79K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.5% | 2,057 | 1,793 | $69K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.1% | 899 | 834 | $63K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.8% | 194 | 185 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.6% | 731 | 547 | $45K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.6% | 1,963 | 1,789 | $45K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.2% | 907 | 823 | $40K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 7,376 | 4,604 | $31K |
| 83735 | 2.2% | 8,020 | 3,534 | $27K |
89 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.1% | 712 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 2,972 | $25K |
| 87641 | 1.8% | 984 | $22K | |
| 84484 | 1.8% | 4,959 | $22K | |
| 82805 | 1.5% | 704 | $19K | |
| 87040 | 1.4% | 1,407 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 736 | $17K |
| 83690 | 1.3% | 4,975 | $17K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 719 | $17K |
| 88342 | 1.3% | 829 | $16K | |
| 83880 | 1.2% | 1,261 | $15K | |
| 81025 | <1% | 4,652 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,967 | $10K |
| 81001 | <1% | 6,739 | $10K | |
| 83605 | <1% | 1,786 | $9K | |
| 88312 | <1% | 384 | $8K | |
| 84703 | <1% | 2,157 | $8K | |
| 85610 | <1% | 3,617 | $7K | |
| 85730 | <1% | 2,069 | $7K | |
| 85027 | <1% | 1,998 | $6K | |
| 80061 | Lipid panel | <1% | 1,478 | $6K |
| 82607 | <1% | 920 | $5K | |
| 86780 | <1% | 604 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,590 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 567 | $5K |
| 87186 | <1% | 588 | $5K | |
| 85379 | <1% | 1,189 | $4K | |
| 87634 | <1% | 165 | $4K | |
| 82962 | <1% | 2,364 | $4K | |
| 86850 | <1% | 1,175 | $3K | |
| 86901 | <1% | 1,507 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 421 | $3K |
| 81003 | <1% | 2,938 | $3K | |
| 84100 | <1% | 1,346 | $3K | |
| 82550 | <1% | 1,037 | $3K | |
| 86900 | <1% | 1,505 | $3K | |
| 86140 | <1% | 1,075 | $2K | |
| 82728 | <1% | 633 | $2K | |
| 84439 | <1% | 536 | $2K | |
| 82040 | <1% | 996 | $2K | |
| 83540 | <1% | 630 | $2K | |
| 84702 | <1% | 442 | $2K | |
| 82746 | <1% | 349 | $2K | |
| 80069 | <1% | 410 | $2K | |
| 82553 | <1% | 452 | $2K | |
| 83550 | <1% | 380 | $2K | |
| 87070 | <1% | 436 | $1K | |
| 82803 | <1% | 178 | $1K | |
| 82140 | <1% | 290 | $1K | |
| 83615 | <1% | 465 | $1K | |
| 82570 | <1% | 370 | $915.84 | |
| 87905 | <1% | 170 | $890.40 | |
| 84466 | <1% | 200 | $843.94 | |
| 85652 | <1% | 587 | $754.52 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28 | $700.00 |
| 82010 | <1% | 289 | $698.71 | |
| 87210 | <1% | 280 | $655.46 | |
| 80076 | <1% | 163 | $615.24 | |
| 80050 | General health panel | <1% | 35 | $571.75 |
| 87088 | <1% | 77 | $430.59 | |
| 83789 | <1% | 51 | $368.73 | |
| 86803 | <1% | 42 | $359.91 | |
| 83021 | <1% | 58 | $353.22 | |
| 87205 | <1% | 191 | $343.78 | |
| 83498 | <1% | 40 | $326.00 | |
| 82261 | <1% | 39 | $321.75 | |
| 86038 | <1% | 41 | $321.10 | |
| 86880 | <1% | 106 | $310.30 | |
| 82248 | <1% | 157 | $309.85 | |
| 84550 | <1% | 149 | $307.19 | |
| 83970 | <1% | 18 | $280.08 | |
| 83516 | <1% | 64 | $279.75 | |
| 82077 | <1% | 37 | $227.92 | |
| 87340 | <1% | 32 | $206.45 | |
| 80143 | <1% | 16 | $175.15 | |
| 80179 | <1% | 14 | $167.70 | |
| 87075 | <1% | 25 | $167.06 | |
| 82776 | <1% | 39 | $137.28 | |
| 85045 | <1% | 100 | $124.55 | |
| 84300 | <1% | 53 | $112.36 | |
| 84156 | <1% | 93 | $106.95 | |
| 86592 | <1% | 50 | $98.15 | |
| 82043 | <1% | 27 | $51.22 | |
| 85018 | <1% | 42 | $51.04 | |
| 87081 | <1% | 14 | $43.50 | |
| 83930 | <1% | 18 | $41.94 | |
| 80178 | <1% | 12 | $39.72 | |
| 87147 | <1% | 13 | $25.72 | |
| 85014 | <1% | 14 | $15.08 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.